MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity And Industry Investment

The UK’s drug regulator, the MHRA, has taken a hit in terms of capacity and funding post-Brexit, and could benefit from government backing to rebuild its regulatory capacity, a leading venture capitalist has said.